Drug Profile
Research programme: Anti-bacterials - KBP Biosciences
Alternative Names: KBP 7909; KBP-7963Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator KBP Biosciences
- Class
- Mechanism of Action Bacterial outer membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections; Gram-positive infections; Pseudomonal infections
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Gram-negative infections in China (PO) (KBP Biosciences pipeline, April 2023)
- 25 Apr 2023 Discontinued - Preclinical for Gram-positive infections in China (PO) (KBP Biosciences pipeline, April 2023).
- 25 Apr 2023 Discontinued - Preclinical for Pseudomonal infections in China (unspecified route) (KBP Biosciences pipeline, April 2023)